Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
26.36
-0.76 (-2.80%)
Mar 9, 2026, 3:04 PM EDT - Market open
Castle Biosciences Employees
Castle Biosciences had 883 employees as of December 31, 2025. The number of employees increased by 122 or 16.03% compared to the previous year.
Employees
883
Change (1Y)
122
Growth (1Y)
16.03%
Revenue / Employee
$389,840
Profits / Employee
-$27,359
Market Cap
783.71M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Neogen | 2,974 |
| Myriad Genetics | 2,700 |
| NeoGenomics | 2,500 |
| OPKO Health | 2,275 |
| Fulgent Genetics | 1,315 |
| GeneDx Holdings | 1,300 |
| GRAIL | 1,000 |
| CareDx | 765 |
CSTL News
- 8 hours ago - DecisionDx®-Melanoma's i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk - GlobeNewsWire
- 4 days ago - Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma's i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB - GlobeNewsWire
- 5 days ago - Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas - GlobeNewsWire
- 10 days ago - Castle Biosciences, Inc. (CSTL) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results - GlobeNewsWire
- 17 days ago - Prospective Validation Study in JAAD Demonstrates Castle Biosciences' AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis - GlobeNewsWire
- 4 weeks ago - Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026 - GlobeNewsWire
- 4 weeks ago - Allspring Emerging Growth Fund Q4 2025 Performance Review - Seeking Alpha